Company:  KERYX BIOPHARMACEUTICALS ... (KERX)
Form Type:  10-Q
Filing Date:  11/8/2018 
CIK:  0001114220 
Address:  ONE MARINA PARK DR. 
City, State, Zip:  BOSTON, Massachusetts 02210 
Telephone:  617-466-3500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.70  
Change: 
-0.26 (-8.78%)  
Trade Time: 
Nov 19  
Market Cap: 
$325.02M
Trade KERX now with 

© 2018  
Description of Business
We are a commercial stage biopharmaceutical company focused on bringing innovative medicines to people with kidney disease. Our long-term vision is to build a multi-product kidney care company. Our marketed product, Auryxia (ferric citrate) tablets, is an orally available, absorbable, iron-based medicine. Auryxia is approved by the U.S. Food and Drug Administration, or FDA, for two indications. Auryxia was originally approved in September 2014 for the control of serum phosphorus levels in patients with chronic kidney disease, or CKD, on dialysis. Additionally, in November 2017, the FDA approved Auryxia for the treatment of iron deficiency anemia in adults with CKD, not on dialysis. With two FDA-approved indications, we will leverage our U.S. clinical and commercial infrastructure to make Auryxia available to millions of people with CKD and either iron deficiency anemia or elevated levels of serum phosphorus, which is referred to as hyperphosphatemia.
Register and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements
          NOTE 15 - SUBSEQUENT EVENTS
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II. OTHER INFORMATION
      ITEM 1. LEGAL PROCEEDINGS
      ITEM 1A. RISK FACTORS
      ITEM 5. OTHER INFORMATION
      ITEM 6. EXHIBITS
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 10.2
  EXHIBIT 31.1
    CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE
  EXHIBIT 31.2
    CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION 302 OF THE
  EXHIBIT 32.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF
  EXHIBIT 32.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER OF